LUNG-MAP
A lung cancer precision medicine trial

VOLUME 12 | WINTER 2020 NEWSLETTER WWW.LUNG-MAP.ORG

2019: Year of Major Momentum

In January 2019, we launched our new master protocol. Now, one year later, we've got great news to share. It's all in the numbers:

709 number of sites with trial open

49 number of states with trial available

19 number of sites with 10 or more patients enrolled

3 accruing sub-studies: S1900A, S1800A, and S1400F Cohort 2

368 sub-study assignments

96 sub-study registrations

862 screening registrations

516 pre-screened prior to progression on current treatment

346 screened at progression on prior treatment

TOP ACCRUING SITES

1	UPMC Hillman Cancer Center, Pittsburgh, PA	**42**
2.	Missouri Baptist Medical Center, St. Louis, MO	**23**
3.	Mercy Medical Center, Baltimore, MD	**20**
4.	University of Oklahoma Health Sciences Center, Oklahoma City, OK	**17**
5.	Mercy Hospital St. Louis, St. Louis, MO	**16**
5.	UNM Comprehensive Cancer Center, Albuquerque, NM	**16**
5.	Wilmot Cancer Institute, Rochester, NY	**16**
6.	Northside Hospital, Atlanta, GA	**15**
7.	Palo Alto Medical Foundation, Santa Cruz, CA	**14**
7.	Essentia Health Cancer Center, Duluth, MN	**14**
7.	Good Samaritan Hospital, Cincinnati, OH	**14**
8.	Regions Hospital, St. Paul, MN	**12**
8.	Roswell Park Comprehensive Cancer Center, Buffalo, NY	**12**
9.	Illinois CancerCare, Peoria, IL	**11**
10.	UK Markey Cancer Center, Lexington, KY	**10**
10.	Anne Arundel Medical Center, Annapolis, MD	**10**
10.	Ascension Providence Hospital, Southfield Campus, Southfield, MI	**10**
10.	Edwards Comprehensive Cancer Center, Huntington, WV	**10**

All data reflects trial activity as of Dec. 31, 2019

LUNG-MAP

A lung cancer precision medicine trial

2020: More Patient Options Coming

We have three new sub-studies slated to open in early 2020. Here are the new treatments coming up fast in the pipeline.

1) **Sub-study:** S1900C "A Phase II Study of Talazoparib Plus Avelumab In Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations"

   Accrual goal: 44

   Activation date: Q1 2020

   Industry partner: Pfizer

   Primary objective: Evaluate the response rate with the PARP inhibitor talazoparib plus the monoclonal antibody avelumab in patients with Stage IV or recurrent, non-squamous non-small cell lung cancer bearing pathogenic STK11 genomic alterations who were previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy

2) **Sub-study:** S1900B "A Phase II Study of LOXO-292 in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer"

   Accrual goal: 124

   Activation date: Q1 2020

   Industry partner: Loxo at Lilly

   Primary objective: Evaluate the response rate to LOXO-292 – a novel, highly selective, ATP-competitive small molecule RET inhibitor – in patients with previously-treated stage IV or recurrent RET fusion-positive non-small cell lung cancer

3) **Sub-study:** S1900D "A Randomized Phase II Study of Sapanisertib Plus Docetaxel Versus Standard of Care in Patients with Previously-Treated NFE2L2 or KEAP1-Positive Stage IV or Recurrent Squamous Cell Lung Cancer"

   Accrual goal: 94

   Activation date: Q1 2020

   Industry partner: Takeda Pharmaceuticals

   Primary objective: Compare the progression-free survival between patients with NFE2L2 or KEAP1-positive Stage IV or recurrent squamous cell lung cancer randomized to an mTOR inhibitor + docetaxel versus standard of care therapy

LUNG-MAP TIP:

When possible, please submit tissue blocks rather than slides. Tissue blocks are more likely to result in successful biomarker profiling, especially for the S1900A biomarker.



CONTACT US

Protocol & Regulatory Questions
lgildner@swog.org or mnorman@swog.org

Eligibility & Data Submission Questions
LUNGMAPQuestion@crab.org

General Medical Questions
LUNGMAP@swog.org

S1900A Medical Questions
S1900AMedicalQuery@swog.org

S1800A Medical Questions
S1800AMedicalQuery@swog.org

S1400F Medical Questions
S1400FMedicalQuery@swog.org

Central Monitoring Questions
centralmonitorquestion@crab.org

Quality Assurance Auditing Questions
qamail@swog.org

Funding Questions
funding@swog.org